Dynavax's hepatitis B vaccine gets FDA nod on third try, shares up

(Reuters) - Dynavax Technologies Corp's hepatitis B vaccine won the U.S. Food and Drug Administration's approval on the third attempt and Chief Executive Eddie Gray told Reuters the company was open to, but not waiting for, a partner to market the drug.